A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07532902
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986504 — DRUG
    BMS-986504 PO daily
  • Ipilimumab — DRUG
    Ipilimumab (1mg/kg Q6wk)
  • Nivolumab — DRUG
    Nivolumab (360mg flat dose Q3wk)
  • 5-FU — DRUG
    are continued until disease progression or intolerance
  • Leucovorin — DRUG
    are continued until disease progression or intolerance
  • Oxaliplatin — DRUG
    are continued until disease progression or intolerance
  • Gemcitabine — DRUG
    Gemcitabine are given for a maximum of 6 cycles
  • Platinum — DRUG
    Platinum are given for a maximum of 6 cycles

Study Details

The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.

Key Dates

Start date
Apr 7, 2026
Status verified
Apr 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Diffuse pleural mesothelioma (DPM): first-line treatment
    Participants will receive BMS-986504 + ipilimumab and nivolumab.
  • Experimental: Gastroesophageal carcinoma (GEC): first-line treatment
    Participants will receive BMS-986504 + FOLFOX and nivolumab.
  • Experimental: Urothelial carcinoma (UC): second- or third-line treatment
    Participants will receive either BMS-986504 + gemcitabine and carboplatin or BMS-986504 + gemcitabine and cisplatin. After that, BMS-986504 monotherapy is continued.

Primary Outcome Measure

determine a recommended phase II dose (RP2D) of BMS-986504 in combination with standard-of-care therapy [ Time Frame: 2 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking RidgeNew Jersey07920
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Monmouth (All Protocol Activities)MiddletownNew Jersey07748
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Bergen (All Protocol Activities)MontvaleNew Jersey07645
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)CommackNew York11725
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Westchester (All Protocol Activities)HarrisonNew York10604
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Michael Offin, MD
646-608-3763
Memorial Sloan Kettering Nassau (All Protocol Activities)UniondaleNew York11553
Michael Offin, MD
646-608-3763

Find similar trials in Basking Ridge, NJ

By condition
Bladder cancer
By specialty
OncologyUrology
By research site
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (All Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (All Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk - Commack (All Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (All Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies